CN108542923A - A kind of application from the melanin extracted in black fungus in liver-protecting product - Google Patents
A kind of application from the melanin extracted in black fungus in liver-protecting product Download PDFInfo
- Publication number
- CN108542923A CN108542923A CN201810491918.9A CN201810491918A CN108542923A CN 108542923 A CN108542923 A CN 108542923A CN 201810491918 A CN201810491918 A CN 201810491918A CN 108542923 A CN108542923 A CN 108542923A
- Authority
- CN
- China
- Prior art keywords
- liver
- melanin
- black fungus
- protecting product
- hepatic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 title claims abstract description 140
- 241000233866 Fungi Species 0.000 title claims abstract description 38
- 230000002440 hepatic effect Effects 0.000 claims abstract description 38
- 210000004185 liver Anatomy 0.000 claims abstract description 27
- 230000000694 effects Effects 0.000 claims abstract description 15
- 239000004615 ingredient Substances 0.000 claims abstract description 13
- 238000001556 precipitation Methods 0.000 claims abstract description 13
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims abstract description 12
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims abstract description 9
- 235000013305 food Nutrition 0.000 claims abstract description 9
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 8
- 238000000605 extraction Methods 0.000 claims abstract description 7
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 5
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 5
- 235000019441 ethanol Nutrition 0.000 claims abstract description 4
- 239000002253 acid Substances 0.000 claims abstract description 3
- 239000012670 alkaline solution Substances 0.000 claims abstract description 3
- 238000000746 purification Methods 0.000 claims abstract description 3
- 239000000047 product Substances 0.000 claims description 21
- 239000000463 material Substances 0.000 claims description 11
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 9
- 239000000203 mixture Substances 0.000 claims description 9
- 239000000843 powder Substances 0.000 claims description 8
- 239000006228 supernatant Substances 0.000 claims description 7
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 6
- 239000003094 microcapsule Substances 0.000 claims description 5
- 239000002552 dosage form Substances 0.000 claims description 4
- 238000001035 drying Methods 0.000 claims description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 4
- 239000012901 Milli-Q water Substances 0.000 claims description 3
- 239000002775 capsule Substances 0.000 claims description 3
- 239000008367 deionised water Substances 0.000 claims description 3
- 229910021641 deionized water Inorganic materials 0.000 claims description 3
- 239000008187 granular material Substances 0.000 claims description 3
- 239000007788 liquid Substances 0.000 claims description 3
- 239000006187 pill Substances 0.000 claims description 3
- 239000000243 solution Substances 0.000 claims description 3
- 239000006188 syrup Substances 0.000 claims description 3
- 235000020357 syrup Nutrition 0.000 claims description 3
- 238000002604 ultrasonography Methods 0.000 claims description 3
- 239000002202 Polyethylene glycol Substances 0.000 claims description 2
- 229920002472 Starch Polymers 0.000 claims description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 2
- 235000019359 magnesium stearate Nutrition 0.000 claims description 2
- JMZOMFYRADAWOG-UHFFFAOYSA-N methyl 7-methoxy-4-(7-methoxy-5-methoxycarbonyl-1,3-benzodioxol-4-yl)-1,3-benzodioxole-5-carboxylate Chemical compound COC(=O)C1=CC(OC)=C2OCOC2=C1C1=C2OCOC2=C(OC)C=C1C(=O)OC JMZOMFYRADAWOG-UHFFFAOYSA-N 0.000 claims description 2
- 229920001223 polyethylene glycol Polymers 0.000 claims description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 2
- 239000002244 precipitate Substances 0.000 claims description 2
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 claims description 2
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 claims description 2
- 235000019698 starch Nutrition 0.000 claims description 2
- 239000008107 starch Substances 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims description 2
- -1 vina Substances 0.000 claims description 2
- 239000003814 drug Substances 0.000 abstract description 17
- 229940079593 drug Drugs 0.000 abstract description 9
- 208000004930 Fatty Liver Diseases 0.000 abstract description 5
- 206010019708 Hepatic steatosis Diseases 0.000 abstract description 5
- 208000010706 fatty liver disease Diseases 0.000 abstract description 5
- 231100000753 hepatic injury Toxicity 0.000 abstract description 5
- 231100000240 steatosis hepatitis Toxicity 0.000 abstract description 5
- 206010019799 Hepatitis viral Diseases 0.000 abstract description 3
- 230000001476 alcoholic effect Effects 0.000 abstract description 3
- 230000008092 positive effect Effects 0.000 abstract description 3
- 230000002265 prevention Effects 0.000 abstract description 3
- 238000000034 method Methods 0.000 abstract description 2
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 210000002966 serum Anatomy 0.000 description 15
- 239000013641 positive control Substances 0.000 description 10
- 230000006378 damage Effects 0.000 description 9
- 241000699670 Mus sp. Species 0.000 description 8
- 241000699666 Mus <mouse, genus> Species 0.000 description 7
- 230000003908 liver function Effects 0.000 description 6
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 5
- WSMYVTOQOOLQHP-UHFFFAOYSA-N Malondialdehyde Chemical compound O=CCC=O WSMYVTOQOOLQHP-UHFFFAOYSA-N 0.000 description 4
- 230000007423 decrease Effects 0.000 description 4
- 210000005229 liver cell Anatomy 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 description 3
- 108010082126 Alanine transaminase Proteins 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 230000003859 lipid peroxidation Effects 0.000 description 3
- 210000005228 liver tissue Anatomy 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 241000196324 Embryophyta Species 0.000 description 2
- 206010019837 Hepatocellular injury Diseases 0.000 description 2
- 101150087188 Mast1 gene Proteins 0.000 description 2
- 241001529936 Murinae Species 0.000 description 2
- 108090000340 Transaminases Proteins 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 208000002672 hepatitis B Diseases 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 208000019423 liver disease Diseases 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 230000003647 oxidation Effects 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 230000035479 physiological effects, processes and functions Effects 0.000 description 2
- 239000000049 pigment Substances 0.000 description 2
- 231100000614 poison Toxicity 0.000 description 2
- 150000003254 radicals Chemical class 0.000 description 2
- 230000008929 regeneration Effects 0.000 description 2
- 238000011069 regeneration method Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 102000014898 transaminase activity proteins Human genes 0.000 description 2
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 235000001674 Agaricus brunnescens Nutrition 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 241001582888 Lobus Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000736075 Schisandra Species 0.000 description 1
- 235000008422 Schisandra chinensis Nutrition 0.000 description 1
- 208000034189 Sclerosis Diseases 0.000 description 1
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 1
- 102000019197 Superoxide Dismutase Human genes 0.000 description 1
- 108010012715 Superoxide dismutase Proteins 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 210000005252 bulbus oculi Anatomy 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000019522 cellular metabolic process Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000002279 cholagogic effect Effects 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000001784 detoxification Methods 0.000 description 1
- 238000003912 environmental pollution Methods 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 231100000437 hepatocellular injury Toxicity 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 230000002443 hepatoprotective effect Effects 0.000 description 1
- 150000002475 indoles Chemical class 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 231100000849 liver cell damage Toxicity 0.000 description 1
- 231100000832 liver cell necrosis Toxicity 0.000 description 1
- 238000007449 liver function test Methods 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 229940100688 oral solution Drugs 0.000 description 1
- 150000002989 phenols Chemical class 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 230000007096 poisonous effect Effects 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 230000001376 precipitating effect Effects 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000009758 senescence Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 201000001862 viral hepatitis Diseases 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L31/00—Edible extracts or preparations of fungi; Preparation or treatment thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
- A61K31/36—Compounds containing methylenedioxyphenyl groups, e.g. sesamin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/53—Liquid-solid separation, e.g. centrifugation, sedimentation or crystallization
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Virology (AREA)
- Mycology (AREA)
- Organic Chemistry (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Polymers & Plastics (AREA)
- Microbiology (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Food Science & Technology (AREA)
- Nutrition Science (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Alternative & Traditional Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention discloses a kind of applications from the melanin extracted in black fungus in liver-protecting product, belong to medicine and food technology field.Black fungus fructification is destroyed the protein in black fungus fructification by the present invention by strong acid, melanin is precipitated out by alkaline solution again, it collects precipitation and obtains melanin coarse extraction, it is purified successively by ethyl alcohol, ethyl acetate, acetone again, melanin after purification is obtained, and uses it for liver-protecting product(Including hepatic or food with effect of hepatic protection)In, the weight percent that wherein melanin ingredient accounts for liver-protecting product is 0.1 ~ 100%.The present invention will be used for from the melanin extracted in black fungus in liver-protecting product, and effective liver protection ingredient melanin has positive effect for virus hepatitis, drug induced hepatic injury, alcoholic liver, the prevention of fatty liver or treatment.In addition, present invention process is simple and practicable, and it is at low cost, it is suitable for industrialized production.
Description
Technical field
The invention belongs to medicine and food technology fields, and in particular to a kind of melanin extracted from black fungus is in liver protection
Application in product.
Background technology
Melanin (melanin) is the heterogeneous high-molecular compound made of indoles or phenolic compound oxidation polymerization,
Generally in black, brown or brown, being widely present in animals and plants and microorganism has extensive biological function, natural black
Pigment has effects that nourishing, health, anti-oxidant and anti-aging etc., has caused the great interest of people, but right both at home and abroad
The research of melanin caused by edible mushroom is rarely reported.Currently, related with liver due to the influence of environmental pollution and drug etc.
Disease be in the trend that constantly rises, heavy type hepatitis, liver fibrosis, hepatic sclerosis etc. occupy prodigious ratio, liver in crowd
Disease, which has become, seriously threatens one of primary root of human health.Carbon tetrachloride is the hepatic injury poisonous substance of classics, through liver cell
Metabolism generates free radicals, and causes lipid peroxidation, destroys the complete of liver plasma membrane structure and function, cause liver cell damage and
Necrosis.
Hepatoprotective agent refers to the medicine for having the effects that improve liver function, promote liver cell regeneration, enhance liver detoxification function
Object, for clinical liver disease.China is the popular big country of hepatitis B, and the incidence of fatty liver is also relatively high.Existing treatment hepatitis B,
The hepatic of fatty liver includes removing toxic substances class drug, stimulated hepatic cell regeneration class drug, cholagogic class drug, promotes energetic supersession class medicine
Object promotes protein to synthesize class drug and Chinese medicine preparation etc..There are different problems for these hepatic either this or thats.As described in
There are also adverse reactions for Chinese medicine preparation, although Schisandra chinens P.E therein can be effectively reduced serum alkaline phosphatase
Level is still easily bounced after drug withdrawal, and to the effect unobvious of glutamic-oxalacetic transaminease, some patients with chronic liver paddy occur after taking
The phenomenon that raising of careless transaminase.Have again is exactly that late result is poor.
Invention content
It is an object of the invention in view of the shortcomings of the prior art, providing a kind of melanin extracted from black fungus in liver protection
Application in product.Melanin is extracted from black fungus, uses it for hepatic or food, for virus hepatitis, drug
Property hepatic injury, alcoholic liver, fatty liver prevention or treatment have positive effect.
To achieve the above object, the present invention adopts the following technical scheme that:
It is polished into powder after black fungus is dried, destroys the protein in fructification with acid, then precipitate by alkaline solution, it is heavy to collect
Shallow lake obtains melanin coarse extraction, then is purified, and obtained melanin is used in liver-protecting product.
Specifically, being polished into powder after black fungus is dried, by gained black fungus powder, water-bath 1 is small at 60 DEG C in hydrochloric acid
When, be then centrifuged for taking precipitation, add sodium hydroxide solution ultrasound 1 hour after centrifuging and taking supernatant, supernatant, which is adjusted to pH, is
1.5 in 80 DEG C of water-baths 12 hours, centrifuging and taking precipitation;Precipitation is washed with deionized water 4 times, melanin coarse extraction is obtained;By gained
Melanin coarse extraction uses ethyl alcohol, ethyl acetate, acetone, milli-Q water successively again, and it is standby to be positioned over -20 DEG C of preservations after drying precipitation
With melanin sterling being obtained, by melanin after purification in liver-protecting product.
The liver-protecting product includes hepatic or food with effect of hepatic protection.
In the liver-protecting product, the melanin ingredient contained therein extracted from black fungus accounts for the weight of liver-protecting product
It is 0.1 ~ 100% to measure percentage.
The hepatic, when the melanin ingredient contained therein extracted from black fungus accounts for the weight of hepatic
When measuring percentage less than 100%, other compositions are other liver protection ingredients and auxiliary material, other described liver protection ingredients include bifendate,
The auxiliary material includes food starch, polyvinylpyrrolidone, sodium carboxymethylcellulose, magnesium stearate, polyethylene glycol.
The dosage form of the hepatic includes tablet, capsule, granule, dripping pill, microcapsules, vina, syrup, mouth
Take liquid;When dosage form is microcapsules, effective liver protection ingredient(Melanin)The weight percent for accounting for hepatic is 100%.
The beneficial effects of the present invention are:
The present invention will be used for from the melanin extracted in black fungus in liver-protecting product, and effective liver protection ingredient melanin is for viral
Hepatitis, drug induced hepatic injury, alcoholic liver, the prevention of fatty liver or treatment have positive effect.The effect can be by following dynamic
Object experiment shows that the experiment has reacted the black fungus melanin of the present invention to carbon tetrachloride(CCl4)Paddy in hepatic injury mice serum
The influence of superoxide dismutase and malonaldehyde in pyruvic transaminase and the active influence of glutamic-oxalacetic transaminease and liver homogenate.Experiment
Process is as follows:
40 mouse are randomly divided into five groups, every group 10, i.e. positive controls, negative control group, model group, melanin group.
Negative control group, sterile water, positive controls 300mg/kg, administration group 100mg/kg.Adaptable fed after a week, using gavage
Administration, is administered once a day, successive administration seven days.In after the last administration, after being deprived of food but not water, mouse plucks eyeball and takes blood, centrifugation
Afterwards, separation serum is to be measured.After corresponding time cervical dislocation is put to death, about it is put into the same position hepatic tissue of liver lobus sinister rapidly ice-cold
Rinsing is wiped dry to no color with filter paper repeatedly in physiological saline, is weighed, with homogenate and homogenizer preparation liver tissue homogenate liquid,
Centrifuging and taking supernatant detects indices.
1. influence of the melanin to experimental animal weight
Influence of 1 melanin of table to experiment mice weight
From table 1 it can be seen that during experiment, blank group and administration group do not have significant difference, illustrate from from black fungus
The melanin of middle extraction is nontoxic, edible.
2. SOD contents
2 hepatic tissue SOD contents of table
As shown in Table 2, compared with Normal group, SOD activity is substantially reduced in model group murine liver tissue, is had extremely significant
Statistical significance shows that damage causes the decline of mouse liver function, modeling success.Positive controls and melanin administration group are equal
The vigor of SOD in hepatic tissue can effectively be improved.
3. MDA contents
Malonaldehyde (MDA):In organism, in lipid peroxidization occurs for Free Radical, and oxidation final product is malonaldehyde, meeting
Cause the cross-linked polymeric of the life macromolecules such as protein, nucleic acid, and there is cytotoxicity.MDA is that Lipid peroxidation metabolism is most important
One of product, its generation can also aggravate the damage of film therefore MDA contents are in plant senescence physiology and Resistance Physiology research
One common counter can understand the degree of Lipid peroxidation metabolism, with the indirect determination membranous system extent of damage by MDA.
3 Liver MDA of table
As shown in Table 3, compared with Normal group, MDA activity is significantly raised in model group murine liver tissue, has extremely significant
Statistical significance shows that damage causes the decline of mouse liver function, modeling success.Positive controls and melanin administration group are equal
The vigor of MDA in hepatic tissue can effectively be inhibited.
4. ALT contents
ALT (glutamic-pyruvic transaminase)Raising is the important indicator that liver function goes wrong.In common factor, all kinds of livers
Inflammation can cause ALT to increase, this is because liver is by caused by destroying.Glutamic-pyruvic transaminase is primarily present in liver cytoplasm
Interior, intracellular concentration is higher than in serum 1000-3000 times.As long as there is 1% liver cell to be destroyed, so that it may so that sero-enzyme increases
One times.Therefore, glutamic-pyruvic transaminase is the most apparent index of hepatic disorder by world health organisation recommendations.
4 Serum ALT content of table
From table 4:Compared with Normal group, model group mice serum activity is significantly raised, shows that damage causes mouse
The decline of liver function, modeling success.Positive controls and melanin group can effectively inhibit the raising of serum active.With model
Group compares, and positive controls mice serum activity pole significantly reduces, and positive control medicine is effective.Melanin group mice serum activity
Significantly lower than model group, there is significant statistical significance prompt melanin to have significant protection to the damage of caused chmice acute
Effect.
5. AST contents
AST(Glutamic-oxalacetic transaminease)It is the index of liver function test on clinical medicine, for judging whether liver receives damage.Liver
There are two types of isodynamic enzymes for interior glutamic-oxalacetic transaminease, are respectively present in liver cell mitochondria (mAST) and endochylema (sAST), in liver
When lesion that cell is slight, only sAST is released into blood, and mAST can be also discharged into blood in succession when lesion is serious.Therefore serum AST is lived
Property increases with the degree of hepatocellular injury
5 serum AST content of table
As shown in Table 5, compared with Normal group, model group mice serum activity is significantly raised, has extremely significant statistics
Meaning shows that damage causes the decline of mouse liver function, modeling success.Positive controls and melanin administration group can be effective
Inhibition serum active raising.Compared with model group, positive controls mice serum activity pole significantly reduces positive control drug
Object is effective.Melanin group mice serum activity is significantly lower than model group, and there is extremely significant statistical significance to prompt melanin pair
Caused mouse damage has significant protective effect.
Specific implementation mode
Below in conjunction with specific embodiment, the present invention will be further described, but the present invention is not limited only to these embodiments.
Powder will be polished into after the drying of black fungus fructification, by gained black fungus powder in hydrochloric acid water-bath 1 hour at 60 DEG C,
Be then centrifuged for taking precipitation, add sodium hydroxide solution ultrasound 1 hour after centrifuging and taking supernatant, by supernatant be adjusted to pH be 1.5
In 80 DEG C of water-baths 12 hours, centrifuging and taking precipitation;Precipitation is washed with deionized water 4 times, then passes sequentially through ethyl alcohol, ethyl acetate, third
Ketone, milli-Q water, drying are positioned over -20 DEG C after precipitating and save backup, and obtain purer melanin.Its pigment content of detection
For 2500-3000mg/kg.
Embodiment 1
It will be used in hepatic from the melanin extracted in black fungus, tablet be made;Melanin accounts for the weight hundred of hepatic
It is 0.1% to divide ratio, and other compositions are auxiliary material.
Embodiment 2
It will be used in hepatic from the melanin extracted in black fungus, granule be made;Melanin accounts for the weight of hepatic
Percentage is 50.0%, and other compositions are auxiliary material.
Embodiment 3
It will be used in hepatic from the melanin extracted in black fungus, capsule be made;Melanin accounts for the weight of hepatic
Percentage is 75%, and other compositions are auxiliary material.
Embodiment 4
It will be used in hepatic from the melanin extracted in black fungus, microcapsules be made;Melanin accounts for the weight of hepatic
Percentage is 100%.
Embodiment 5
It will be used in hepatic from the melanin extracted in black fungus, dripping pill be made;Melanin accounts for the weight hundred of hepatic
It is 5% to divide ratio, and other compositions are auxiliary material.
Embodiment 6
It will be used in hepatic from the melanin extracted in black fungus, vina be made;Melanin accounts for the weight hundred of hepatic
It is 25% to divide ratio, and other compositions are auxiliary material.
Embodiment 7
It will be used in hepatic from the melanin extracted in black fungus, oral solution be made;Melanin accounts for the weight of hepatic
Percentage is 20%, and other compositions are auxiliary material.
Embodiment 8
It will be used in hepatic from the melanin extracted in black fungus, syrup be made;Melanin accounts for the weight of hepatic
Percentage is 30%, and other compositions are auxiliary material.
The foregoing is merely presently preferred embodiments of the present invention, all equivalent changes done according to scope of the present invention patent with
Modification should all belong to the covering scope of the present invention.
Claims (6)
1. a kind of application from the melanin extracted in black fungus in liver-protecting product, it is characterised in that:After black fungus is dried
It is polished into powder, destroys the protein in fructification with acid, then precipitate by alkaline solution, collection precipitation obtains melanin and slightly carries
Object, then purified, obtained melanin is used in liver-protecting product.
2. a kind of application from the melanin extracted in black fungus in liver-protecting product according to claim 1, feature
It is:Powder is polished into after black fungus is dried, by gained black fungus powder in hydrochloric acid water-bath 1 hour at 60 DEG C, be then centrifuged for
Precipitation is taken, adds sodium hydroxide solution ultrasound centrifuging and taking supernatant after 1 hour, it is 1.5 in 80 DEG C of water that supernatant, which is adjusted to pH,
Bath 12 hours, centrifuging and taking precipitation;Precipitation is washed with deionized water 4 times, melanin coarse extraction is obtained;By gained melanin coarse extraction
Use ethyl alcohol, ethyl acetate, acetone and milli-Q water successively again, being positioned over -20 DEG C after drying precipitation saves backup, and is purified
Melanin afterwards, by melanin after purification in liver-protecting product.
3. a kind of application from the melanin extracted in black fungus in liver-protecting product according to claim 1 or 2, special
Sign is:The liver-protecting product includes hepatic or food with effect of hepatic protection.
4. a kind of application from the melanin extracted in black fungus in liver-protecting product according to claim 3, feature
It is:In the liver-protecting product, the melanin ingredient contained therein extracted from black fungus accounts for the weight of liver-protecting product
Percentage is 0.1 ~ 100%.
5. a kind of application from the melanin extracted in black fungus in liver-protecting product according to claim 3, feature
It is:The hepatic, when the melanin ingredient contained therein extracted from black fungus accounts for the weight of hepatic
When percentage is less than 100%, other compositions are other liver protection ingredients and auxiliary material, other described liver protection ingredients include bifendate, institute
It includes food starch, polyvinylpyrrolidone, sodium carboxymethylcellulose, magnesium stearate, polyethylene glycol to state auxiliary material.
6. a kind of application from the melanin extracted in black fungus in liver-protecting product according to claim 3, feature
It is:The dosage form of the hepatic includes tablet, capsule, granule, dripping pill, microcapsules, vina, syrup, takes orally
Liquid;When dosage form is microcapsules, the weight percent that effective liver protection ingredient accounts for hepatic is 100%.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201810491918.9A CN108542923A (en) | 2018-05-22 | 2018-05-22 | A kind of application from the melanin extracted in black fungus in liver-protecting product |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201810491918.9A CN108542923A (en) | 2018-05-22 | 2018-05-22 | A kind of application from the melanin extracted in black fungus in liver-protecting product |
Publications (1)
Publication Number | Publication Date |
---|---|
CN108542923A true CN108542923A (en) | 2018-09-18 |
Family
ID=63495402
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201810491918.9A Pending CN108542923A (en) | 2018-05-22 | 2018-05-22 | A kind of application from the melanin extracted in black fungus in liver-protecting product |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN108542923A (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109549959A (en) * | 2018-11-29 | 2019-04-02 | 福建农林大学 | A method of black fungus melanin is extracted using cellulase-ultrasonic synergistic |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104382953A (en) * | 2014-11-28 | 2015-03-04 | 哈尔滨墨医生物技术有限公司 | Extraction method of melanin in black fungi |
-
2018
- 2018-05-22 CN CN201810491918.9A patent/CN108542923A/en active Pending
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104382953A (en) * | 2014-11-28 | 2015-03-04 | 哈尔滨墨医生物技术有限公司 | Extraction method of melanin in black fungi |
Non-Patent Citations (4)
Title |
---|
吴晨霞等: "木耳黑色素的提取及其抗氧化研究 ", 《食用菌》 * |
张莲姬等: "黑木耳中黑色素的提取及其稳定性研究 ", 《山东农业大学学报(自然科学版)》 * |
权启镇: "《新肝脏病学》", 31 January 2003, 山东科学技术出版社 * |
黄峻: "《临床药物手册》", 31 January 2015, 上海科学技术出版社 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109549959A (en) * | 2018-11-29 | 2019-04-02 | 福建农林大学 | A method of black fungus melanin is extracted using cellulase-ultrasonic synergistic |
CN109549959B (en) * | 2018-11-29 | 2021-07-23 | 福建农林大学 | Method for extracting black fungus melanin by using cellulase-ultrasonic wave synergism |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN101301310B (en) | Use of brown alga polysaccharide sulfate in preventing and treating Parkinson's disease | |
CN104623201B (en) | A kind of liver protection Elmination of toxicant and fat-lowering hypoglycemic medicine and its application | |
CN104689251B (en) | A kind of Chinese medicine composition, its preparation method and Chinese medicine preparation for alleviating chemical damage | |
CN106474145B (en) | Application of the Polysaccharides from Leaves of Moringa oleifera in preparation prevention and treatment alcoholic liver injury drug and food | |
CN102885726A (en) | Eucommia extract product, its preparation method and application thereof | |
CN106310236A (en) | Antioxidation SOD oral spray and preparing method thereof | |
CN103191214A (en) | Preparation for relieving or neutralizing effect of alcohol and protecting liver | |
CN108542923A (en) | A kind of application from the melanin extracted in black fungus in liver-protecting product | |
CN1293041A (en) | Functional food for protecting liver and medicine for preventing and curing hepatitides prepared from loach and its preparing process | |
CN109589400B (en) | Composition with neuroprotective effect | |
CN101244084B (en) | Sobering-up agent of pearl oyster and preparation thereof | |
CN102860496A (en) | Oxidation-resisting health-care food for improving immunity and preparation method thereof | |
CN110801456A (en) | Application of cordycepin in preparation of liver protection product | |
CN108714164A (en) | The purposes of Folium Forsythia black tea extract | |
CN112807375B (en) | Application of Wangshi Baochi pill in preparation of medicine for preventing and/or treating alcoholic liver injury | |
CN101503721B (en) | Method for extracting swan-mussel polysaccharide | |
CN104667196B (en) | There is composition, preparation method and the Chinese medicine preparation of protective effect to the liver of chemical lesion | |
CN114009795A (en) | Giant salamander peptide nutritional composition for protecting liver | |
CN106727626A (en) | Application of 1,6 diphosphofructose in treatment alcoholic hepatic injury medicine is prepared | |
CN1907432A (en) | Application of polysaccharide from the Gastrodia elata Blume in health caring stuff and medicine | |
CN104367612B (en) | A kind of application of dog ant grass extract | |
CN105770565A (en) | Liver injury treating and in-vivo autioxidant enzyme activity enhancing composition and application thereof | |
CN101361799B (en) | Composition containing brown alga polysaccharide sulfuric ester and schisandra chinensis and use thereof | |
CN101596268B (en) | Application of garlic total saponin in preparing medicaments and foods for resisting oxidative stress damage | |
CN115501294B (en) | Preparation method and application of saccharomyces boulardii fermentation dioscorea opposita alcohol extract |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20180918 |
|
RJ01 | Rejection of invention patent application after publication |